We serve the needs of pets and their people
Kedi Bioscience leverages validated drug targets and unique insights into animals to build advanced products for pets
Our platform technology yielded potent and developable drug candidates. We are advancing a pipeline of wholly owned assets to address a range of prevalent feline diseases.
Oncology
Lead programs - Felis catus
Metabolic
Early pre-clinical - Felis catus
Autoimmune
Infectious
Targets identified - Multiple species
Early pre-clinical - Felis catus
Pain
Target Discovery - Multiple species
We are looking for innovative partners to complement our drug development programs.
We are flexible, reasonable business partners with a commitment to animal welfare.
Get in touch to learn more about our pipeline assets.